Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
THE EFFECTS OF COENZYME Q(10) TREATMENT ON MATERNALLY INHERITED DIABETES-MELLITUS AND DEAFNESS, AND MITOCHONDRIAL-DNA 3243 (A TO G) MUTATION
Autore:
SUZUKI S; HINOKIO Y; OHTOMO M; HIRAI M; HIRAI A; CHIBA M; KASUGA S; SATOH Y; AKAI H; TOYOTA T;
Indirizzi:
TOHOKU UNIV,SCH MED,DEPT INTERNAL MED 3,AOBA KU,SEIRYOU MACHI 1-1 SENDAI MIYAGI 980 JAPAN
Titolo Testata:
Diabetologia
fascicolo: 5, volume: 41, anno: 1998,
pagine: 584 - 588
SICI:
0012-186X(1998)41:5<584:TEOCQT>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
KEARNS-SAYRE SYNDROME; LACTIC-ACIDOSIS; EPISODES MELAS; POINT MUTATION; ENCEPHALOMYOPATHY; THERAPY; GENE; ENCEPHALOPATHY; IMPROVEMENT; ANTIOXIDANT;
Keywords:
DEAFNESS; MITOCHONDRIAL DNA MUTATION; INSULIN; C-PEPTIDE; LACTATE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
24
Recensione:
Indirizzi per estratti:
Citazione:
S. Suzuki et al., "THE EFFECTS OF COENZYME Q(10) TREATMENT ON MATERNALLY INHERITED DIABETES-MELLITUS AND DEAFNESS, AND MITOCHONDRIAL-DNA 3243 (A TO G) MUTATION", Diabetologia, 41(5), 1998, pp. 584-588

Abstract

The characteristic clinical features of diabetes mellitus with mitochondrial DNA (mtDNA) 3243(A-G) mutation are progressive insulin secretory defect, neurosensory deafness and maternal inheritance, referred toas maternally inherited diabetes mellitus and deafness (MIDD). A treatment for MIDD to improve insulin secretory defects and reduce deafness has not been established. The effects of coenzyme Q(10) (CoQ(10)) treatment on insulin secretory response, hearing capacity and clinical symptoms of MIDD were investigated. 28 MIDD patients (CoQ(10)-DM), 7 mutant subjects with impaired glucose tolerance (IGT), and 15 mutant subjects with normal glucose tolerance (NGT) were treated daily with oraladministration of 150 mg of CoQ(10) for 3 years. Insulin secretory response, blood lactate after exercise, hearing capacity and other laboratory examinations were investigated every year, In the same way we evaluated 16 MIDD patients (control-DM). 5 mutant IGT and 5 mutant NGT subjects in yearly examinations. The insulin secretory response assessed by glucagon-induced C-peptide secretion and 24 h urinary C-peptide excretion after 3 years in the CoQ(10)-DM group was significantly higher than that in the control-DM group. CoQ(10) therapy prevented progressive hearing loss and improved blood lactate after exercise in the MIDD patients. CoQ(10) treatment did not affect the diabetic complications or other clinical symptoms of MIDD patients. CoQ(10) treatment did not affect the insulin secretory capacity of the mutant IGT and NGT subjects. There were no side effects during therapy This is the first report demonstrating the therapeutic usefulness of CoQ(10) on MIDD.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 12:32:05